BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 32217742)

  • 1. A Highly Potent TACC3 Inhibitor as a Novel Anticancer Drug Candidate.
    Akbulut O; Lengerli D; Saatci O; Duman E; Seker UOS; Isik A; Akyol A; Caliskan B; Banoglu E; Sahin O
    Mol Cancer Ther; 2020 Jun; 19(6):1243-1254. PubMed ID: 32217742
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FGFR3-TACC3 cancer gene fusions cause mitotic defects by removal of endogenous TACC3 from the mitotic spindle.
    Sarkar S; Ryan EL; Royle SJ
    Open Biol; 2017 Aug; 7(8):. PubMed ID: 28855393
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A small compound targeting TACC3 revealed its different spatiotemporal contributions for spindle assembly in cancer cells.
    Yao R; Kondoh Y; Natsume Y; Yamanaka H; Inoue M; Toki H; Takagi R; Shimizu T; Yamori T; Osada H; Noda T
    Oncogene; 2014 Aug; 33(33):4242-52. PubMed ID: 24077290
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting TACC3 represents a novel vulnerability in highly aggressive breast cancers with centrosome amplification.
    Saatci O; Akbulut O; Cetin M; Sikirzhytski V; Uner M; Lengerli D; O'Quinn EC; Romeo MJ; Caliskan B; Banoglu E; Aksoy S; Uner A; Sahin O
    Cell Death Differ; 2023 May; 30(5):1305-1319. PubMed ID: 36864125
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transforming fusions of FGFR and TACC genes in human glioblastoma.
    Singh D; Chan JM; Zoppoli P; Niola F; Sullivan R; Castano A; Liu EM; Reichel J; Porrati P; Pellegatta S; Qiu K; Gao Z; Ceccarelli M; Riccardi R; Brat DJ; Guha A; Aldape K; Golfinos JG; Zagzag D; Mikkelsen T; Finocchiaro G; Lasorella A; Rabadan R; Iavarone A
    Science; 2012 Sep; 337(6099):1231-5. PubMed ID: 22837387
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The transforming acidic coiled coil 3 protein is essential for spindle-dependent chromosome alignment and mitotic survival.
    Schneider L; Essmann F; Kletke A; Rio P; Hanenberg H; Wetzel W; Schulze-Osthoff K; Nürnberg B; Piekorz RP
    J Biol Chem; 2007 Oct; 282(40):29273-83. PubMed ID: 17675670
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of a degrader against oncogenic fusion protein FGFR3-TACC3.
    Shibata N; Cho N; Koyama H; Naito M
    Bioorg Med Chem Lett; 2022 Mar; 60():128584. PubMed ID: 35085722
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oncogenic Gene Fusion FGFR3-TACC3 Is Regulated by Tyrosine Phosphorylation.
    Nelson KN; Meyer AN; Siari A; Campos AR; Motamedchaboki K; Donoghue DJ
    Mol Cancer Res; 2016 May; 14(5):458-69. PubMed ID: 26869289
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Detection, Characterization, and Inhibition of FGFR-TACC Fusions in IDH Wild-type Glioma.
    Di Stefano AL; Fucci A; Frattini V; Labussiere M; Mokhtari K; Zoppoli P; Marie Y; Bruno A; Boisselier B; Giry M; Savatovsky J; Touat M; Belaid H; Kamoun A; Idbaih A; Houillier C; Luo FR; Soria JC; Tabernero J; Eoli M; Paterra R; Yip S; Petrecca K; Chan JA; Finocchiaro G; Lasorella A; Sanson M; Iavarone A
    Clin Cancer Res; 2015 Jul; 21(14):3307-17. PubMed ID: 25609060
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recurrent FGFR3-TACC3 fusion gene in nasopharyngeal carcinoma.
    Yuan L; Liu ZH; Lin ZR; Xu LH; Zhong Q; Zeng MS
    Cancer Biol Ther; 2014; 15(12):1613-21. PubMed ID: 25535896
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The centrosomal adaptor TACC3 and the microtubule polymerase chTOG interact via defined C-terminal subdomains in an Aurora-A kinase-independent manner.
    Thakur HC; Singh M; Nagel-Steger L; Kremer J; Prumbaum D; Fansa EK; Ezzahoini H; Nouri K; Gremer L; Abts A; Schmitt L; Raunser S; Ahmadian MR; Piekorz RP
    J Biol Chem; 2014 Jan; 289(1):74-88. PubMed ID: 24273164
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aurora A site specific TACC3 phosphorylation regulates astral microtubule assembly by stabilizing γ-tubulin ring complex.
    Rajeev R; Singh P; Asmita A; Anand U; Manna TK
    BMC Mol Cell Biol; 2019 Dec; 20(1):58. PubMed ID: 31823729
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting TACC3 Induces Immunogenic Cell Death and Enhances T-DM1 Response in HER2-Positive Breast Cancer.
    Gedik ME; Saatci O; Oberholtzer N; Uner M; Akbulut Caliskan O; Cetin M; Aras M; Ibis K; Caliskan B; Banoglu E; Wiemann S; Üner A; Aksoy S; Mehrotra S; Sahin O
    Cancer Res; 2024 May; 84(9):1475-1490. PubMed ID: 38319231
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of TACC3 by a small molecule inhibitor in breast cancer.
    Campo L; Breuer EK
    Biochem Biophys Res Commun; 2018 Apr; 498(4):1085-1092. PubMed ID: 29555478
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oncogenic driver FGFR3-TACC3 requires five coiled-coil heptads for activation and disulfide bond formation for stability.
    Wang CG; Peiris MN; Meyer AN; Nelson KN; Donoghue DJ
    Oncotarget; 2023 Feb; 14():133-145. PubMed ID: 36780330
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TACC3: a multi-functional protein promoting cancer cell survival and aggressiveness.
    Saatci O; Sahin O
    Cell Cycle; 2023; 22(23-24):2637-2655. PubMed ID: 38197196
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Localization of human TACC3 to mitotic spindles is mediated by phosphorylation on Ser558 by Aurora A: a novel pharmacodynamic method for measuring Aurora A activity.
    LeRoy PJ; Hunter JJ; Hoar KM; Burke KE; Shinde V; Ruan J; Bowman D; Galvin K; Ecsedy JA
    Cancer Res; 2007 Jun; 67(11):5362-70. PubMed ID: 17545617
    [TBL] [Abstract][Full Text] [Related]  

  • 18. FGFR3-TACC3 fusion proteins act as naturally occurring drivers of tumor resistance by functionally substituting for EGFR/ERK signaling.
    Daly C; Castanaro C; Zhang W; Zhang Q; Wei Y; Ni M; Young TM; Zhang L; Burova E; Thurston G
    Oncogene; 2017 Jan; 36(4):471-481. PubMed ID: 27345413
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FGFR3 signaling and function in triple negative breast cancer.
    Chew NJ; Nguyen EV; Su SP; Novy K; Chan HC; Nguyen LK; Luu J; Simpson KJ; Lee RS; Daly RJ
    Cell Commun Signal; 2020 Jan; 18(1):13. PubMed ID: 31987043
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TACC3 overexpression in cholangiocarcinoma correlates with poor prognosis and is a potential anti-cancer molecular drug target for HDAC inhibitors.
    He JC; Yao W; Wang JM; Schemmer P; Yang Y; Liu Y; Qian YW; Qi WP; Zhang J; Shen Q; Yang T
    Oncotarget; 2016 Nov; 7(46):75441-75456. PubMed ID: 27705912
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.